在ESMO 2024会议上,Immatics发布了TCER® IMA401的第一阶段试验进展的鼓舞性消息. Immatics releases encouraging Phase 1 trial progress for TCER® IMA401 at ESMO 2024 conference.

在ESMO 2024会议期间,Immatics宣布了其TCR双特异分子TCER® IMA401的有希望的临床概念验证数据,该分子针对MAGEA4/8. Immatics announced promising clinical proof-of-concept data for its TCR bispecific molecule TCER® IMA401, targeting MAGEA4/8, during the ESMO 2024 conference. 第一阶段的试验侧重于表达这些标记的固态肿瘤,随着病人的入学和按期使用剂量,试验继续取得进展。 The Phase 1 trial, focused on solid tumors expressing these markers, continues to progress with patient enrollment and dosing on schedule. 该公司预计很快会收到更多最新数据,预计将在2026年就IMA401做出一项可能的监管决定。 The company expects additional data updates soon, with a potential regulatory decision regarding IMA401 anticipated in 2026.